Advertisement
Advertisement
XLO
Xilio Therapeutics, Inc. Common Stock
8.62
USDSponsored
+0.12
+1.41%
Nov 06, 15:59 UTC -5
Closed
After-Market
8.79
+0.17
+1.91%
Xilio Therapeutics, Inc. Common Stock (XLO) Earnings
XLO Earnings Reports
Positive Surprise Ratio
XLO beat 13 of 20 last estimates.
65%
Next Report
Next Week
Date of Next Report
Nov 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.89M
/-$0.82
Implied change from Q2 26 (Revenue/ EPS)
-73.85%
/+148.48%
Implied change from Q3 25 (Revenue/ EPS)
-74.36%
/+925.00%
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, XLO reported earnings of -0.33 USD per share (EPS) for Q2 26, beating the estimate of -0.59 USD, resulting in a 44.62% surprise. Revenue reached 18.69 million, compared to an expected 12.85 million, with a 45.49% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.82 USD, with revenue projected to reach 4.89 million USD, implying an increase of 148.48% EPS, and decrease of -73.85% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
-$0.02
Surprise
-132.68%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
FAQ
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Xilio Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 44.62%, and revenue of $18.69M, 45.49% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- 0%, changed from $7.73 before the earnings release to $7.73 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 16, 2026.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.82 and revenue of $4.89M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.